rupiya.io
⠋Loading...
0%
❯ Parsing revenue segments...
Anan Drug & Chem Ltd is a listed Indian business company listed on BSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Anan Drug & Chem Ltd makes money through Core products and services, Customer and channel-led sales, Ancillary operating income in its operating segment. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within its sector.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period |
|---|
| Sales |
| Expenses |
| Operating Profit |
| OPM % |
| Other Income |
| Depreciation |
| Interest |
| Profit Before Tax |
| Tax |
| Net Profit |
| EPS (₹) |
| Dividend Payout % |
No quarterly data available.
No balance sheet data available.
No cash flow data available.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Aditya Birla Sun Life BSE Top 10 Banks ETF | ₹0 Cr | 0.0 | 0.00% | 0.00% |
| Aditya Birla Sun Life Nifty Bank ETF | ₹0 Cr | 13.9 | 0.00% | -1.31% |
| Aditya Birla Sun Life CRISIL Liquid Overnight ETF | ₹0 Cr | 0.0 | 0.00% | 0.00% |
| Aditya Birla Sun Life MSCI India ETF | ₹0 Cr | 0.0 | 0.00% | 0.00% |
| Aditya Birla Sun Life Nifty Next 50 ETF | ₹0 Cr | 17.5 | 0.00% | +5.75% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.